漢商集團(600774.SH):子公司擬斥資1950萬元設立漢商生物 專注於醫美產品領域
格隆匯6月23日丨漢商集團(600774.SH)公吿,公司全資子公司漢商大健康產業有限公司(“漢商大健康”)擬以1950萬元人民幣投資設立全資孫公司漢商生物技術(成都)有限公司。
另外,擬在漢商生物成立及團隊成員到位後,由漢商生物團隊成員及相關人員等共同成立有限合夥企業對漢商生物進行增資,以人民幣1050萬元貨幣出資獲得增資後漢商生物35%股權,並在履行相應審批程序後實施。增資完成後,漢商大健康和有限合夥企業分別持有漢商生物65%、35%股權。
此次對外投資將有效集聚公司、團隊等多方資源並專注於醫美產品領域,立足聚乳酸材料的核心技術優勢,圍繞生物材料技術平台進行產品線的打造和拓展,重點開發聚乳酸微球等醫美應用產品,持續推進項目研發落地並不斷尋求新的市場化發展機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.